What question did this study set out to answer?

To evaluate whether integrating carfilzomib and lenalidomide into induction, consolidation, and maintenance regimens improves outcomes for newly diagnosed primary plasma cell leukaemia.

September 15, 2023The Lancet OncologyOpen Access

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study

View Full Paper

Ask AI

Bookmark

Authors

NDNiels W.C.J. van de Donk MMMonique C. Minnema BHBronno van der Holt

Discussion

Member takes

Overview

Non-randomized phase 2 trial demonstrates improved progression-free survival with carfilzomib and lenalidomide in primary plasma cell leukaemia, highlighting the ongoing need for novel...

Key Points

To evaluate whether integrating carfilzomib and lenalidomide into induction, consolidation, and maintenance regimens improves outcomes for newly diagnosed primary plasma cell leukaemia.
Non-randomised, multicentre, phase 2 study (EMN12/HOVON-129; NTR5350) conducted across 19 academic centres in seven European countries among 61 newly diagnosed patients.
Younger patients (aged 18–65 years, n=36) received carfilzomib, lenalidomide, and dexamethasone (KRd) induction, autologous haematopoietic stem-cell transplantation, KRd consolidation, and carfilzomib–lenalidomide maintenance.
Older patients (aged ≥66 years, n=25) received eight cycles of KRd induction followed by continuous carfilzomib and lenalidomide maintenance until disease progression.
Median progression-free survival was 15·5 months (95% CI 9·4–38·4) with median follow-up of 43·5 months in younger patients, and 13·8 months (95% CI 9·2–35·5) with median follow-up of 32·0 months in older patients.
Grade 3 or higher adverse events during the initial four KRd cycles included infections (6% of younger vs 32% of older patients) and respiratory events (6% vs 16%).
Treatment-related serious adverse events occurred in 72% of younger and 76% of older patients, resulting in treatment-related mortality in 0% of younger and 12% (n=3) of older patients.

Cite This Study

Donk et al. (2023) studied this question.

synapsesocial.com/papers/6aa76e394a8f2d1a4489ac7e https://doi.org/10.1016/s1470-2045(23)00405-9

View Full Paper

Ask AI

Bookmark

September 15, 2023The Lancet OncologyOpen Access

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study

View Full Paper

Ask AI

Bookmark

Authors

NDNiels W.C.J. van de Donk MMMonique C. Minnema BHBronno van der Holt

Discussion

Member takes

Overview

Non-randomized phase 2 trial demonstrates improved progression-free survival with carfilzomib and lenalidomide in primary plasma cell leukaemia, highlighting the ongoing need for novel...

Key Points

To evaluate whether integrating carfilzomib and lenalidomide into induction, consolidation, and maintenance regimens improves outcomes for newly diagnosed primary plasma cell leukaemia.
Non-randomised, multicentre, phase 2 study (EMN12/HOVON-129; NTR5350) conducted across 19 academic centres in seven European countries among 61 newly diagnosed patients.
Younger patients (aged 18–65 years, n=36) received carfilzomib, lenalidomide, and dexamethasone (KRd) induction, autologous haematopoietic stem-cell transplantation, KRd consolidation, and carfilzomib–lenalidomide maintenance.
Older patients (aged ≥66 years, n=25) received eight cycles of KRd induction followed by continuous carfilzomib and lenalidomide maintenance until disease progression.
Median progression-free survival was 15·5 months (95% CI 9·4–38·4) with median follow-up of 43·5 months in younger patients, and 13·8 months (95% CI 9·2–35·5) with median follow-up of 32·0 months in older patients.
Grade 3 or higher adverse events during the initial four KRd cycles included infections (6% of younger vs 32% of older patients) and respiratory events (6% vs 16%).
Treatment-related serious adverse events occurred in 72% of younger and 76% of older patients, resulting in treatment-related mortality in 0% of younger and 12% (n=3) of older patients.

Cite This Study

Donk et al. (2023) studied this question.

synapsesocial.com/papers/6aa76e394a8f2d1a4489ac7e https://doi.org/10.1016/s1470-2045(23)00405-9

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark